Infinity Bio, Inc.

BALTIMORE, MD · Founded 2023 · Biotech · Private

MIPSA platform for mapping immune responses across antigen libraries using antibody analysis

Claim this profile

Follows are private to you and power your alerts

Updated · infinitybio.com

Sector
Biotech
Headquarters
BALTIMORE, MD
Founded
2023
Latest Form D
$5M, Aug 2025
Total capital
$9.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$9.5M
3 Form D · last Aug 2025
14 months since last filing
Federal contracts
$11K
1 award · Health and Human S
Rank in Biotech#382 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202320242025FEDERAL ↑EQUITY ↓Cumulative $9.5M$11K1st Form D$2.5M2nd Form D$2M3rd Form D$5M
202320242025FEDERAL ↑EQUITY ↓Cumulative $9.5M$11K1st Form D$2.5M2nd Form D$2M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$5M
  • Private capital raisedForm D · SEC · 2nd filing$2M
  • Federal contractHealth and Human S · Virsight Profiling From African Mosquito Bloodmeals (ambis # 2248955)$11K
  • Private capital raisedForm D · SEC · 1st filing$2.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Benjamin LarmanDirectorNamed in SEC Form D filings
  • Bill Benjamin CampbellDirectorNamed in SEC Form D filings
  • Caroline PopperDirectorNamed in SEC Form D filings
  • Herman M ScholtzDirectorNamed in SEC Form D filings
  • H. Benjamin LarmanExecutive Officer, DirectorNamed in SEC Form D filings
  • Joy M NassifExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
  • Malek Benjamin FahemDirectorNamed in SEC Form D filings
  • Matthew Benjamin HellauerDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • MOLECULAR TRANSFER, INC.Similar federal contract value in Biotech · $13K in contracts
  • SUPERIOR NANO LLCSimilar federal contract value in Biotech · $12K in contracts
  • SPECTRAGENETICSSimilar federal contract value in Biotech · $11K in contracts
  • seqWell Inc.Similar federal contract value in Biotech · $10K in contracts
  • Full Genomes CorpSimilar federal contract value in Biotech · $10K in contracts
  • Cellecta, IncorporatedSimilar federal contract value in Biotech · $9K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .